PCN58 Estimation of Post-Infusion Costs of Care for Patients With Relapsed and Refractory Multiple Myeloma (RRMM) Who Received Idecabtagene Vicleucel (ide-cel, bb2121) in the KarMMa Clinical Trial

Jun 1, 2021, 00:00 AM
10.1016/j.jval.2021.04.150
https://www.valueinhealthjournal.com/article/S1098-3015(21)00367-3/fulltext
Section Title :
Section Order : 10727
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00367-3&doi=10.1016/j.jval.2021.04.150
HEOR Topics :
Tags :
Regions :